Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Orphan drug designation for PV-10 in metastatic melanoma

Jan. 10, 2007

ZEN-012 begins phase I study in solid tumors and lymphoma

Jan. 10, 2007

Interim analysis clears pivotal study of pralatrexate to continue

Jan. 10, 2007

Targepeutics developing targeted molecular therapies for cancer

Jan. 10, 2007

TargeGen selects Jak2 inhibitor TG-101348 for clinical development

Jan. 9, 2007

Semafore completes Series B equity financing

Jan. 9, 2007

U.S. orphan drug status for INNO-406 in Gleevec-resistant or intolerant CML

Jan. 9, 2007

Enzon files IND for HIF-1alpha antagonist

Jan. 9, 2007

Positive findings for pertuzumab plus gemcitabine in phase II trial

Jan. 8, 2007

Aveo acquires license to VEGF receptor inhibitor KRN-951

Jan. 8, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...